Gene Symbol
DLK
Full Name
Dual Leucine Zipper Kinase (MAP3K12)
Chromosome
12p13.2
NCBI Gene ID
[7786](https://www.ncbi.nlm.nih.gov/gene/7786)
OMIM
[604451](https://www.omim.org/entry/604451)
Ensembl ID
[ENSG00000116809](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116809)
UniProt ID
[Q16568](https://www.uniprot.org/uniprot/Q16568)
Associated Diseases
ALS, Alzheimer's Disease, peripheral neuropathy
DLK (Dual Leucine Zipper Kinase, also known as MAP3K12) is a mitogen-activated protein kinase kinase kinase (MAP3K) that plays a critical role in axonal injury signaling. DLK is a key upstream activator of the JNK pathway and has emerged as a promising therapeutic target for neurodegenerative diseases and nerve injury .
DLK functions as a master regulator of the stress-activated protein kinase (SAPK) signaling cascade:
After axonal injury, DLK is rapidly activated and initiates a signaling cascade that:
- Activates MLK4/MLK3 → MKK4/7 → JNK pathway
- Promotes Wallerian degeneration in distal axon segments
- Regulates transcription of pro-apoptotic genes
DLK plays a role in synaptic plasticity and function:
- Regulates synaptic vesicle dynamics
- Modulates axon initial segment integrity
- Influences dendritic spine morphology
Under pathological conditions, DLK can promote neuronal death through:
- JNK-mediated activation of pro-apoptotic proteins (BIM, BAD)
- Caspase activation
- Transcriptional regulation of cell death genes
flowchart TD
A["Axonal Injury / Stress"] --> B["DLK Activation"]
B --> C["MLK4/MLK3"]
C --> D["MKK4/7"]
D --> E["JNK1/2/3"]
E --> F["Multiple Outcomes"]
F --> G["Transcription<br/>c-Jun, ATF2"]
F --> H["Apoptosis<br/>BIM activation"]
F --> I["Axonal Degeneration<br/>Wallerian degeneration"]
G --> J["Inflammation"]
H --> K[" neuronal death"]
DLK is predominantly expressed in:
- Motor neurons — highest expression, relevant to ALS
- Sensory neurons — dorsal root ganglia
- Hippocampus — CA1 region
- Cortex — layer 5 pyramidal neurons
The neuronal expression pattern makes DLK particularly relevant to diseases affecting specific neuron populations.
DLK is strongly implicated in ALS pathogenesis:
- Elevated activation in ALS motor neurons
- Promotes excitotoxicity and oxidative stress
- Genetic inhibition of DLK extends survival in animal models
- Small molecule DLK inhibitors in clinical development
- DLK is elevated in AD brain tissue
- JNK pathway activation correlates with tau pathology
- May contribute to synaptic loss and neuronal death
- DLK mediates chemotherapy-induced peripheral neuropathy
- Involved in diabetic neuropathy
- Inhibition protects against nerve damage
DLK is activated following nerve injury and drives Wallerian degeneration. Inhibition could potentially:
- Preserve injured axons
- Promote regeneration
- Reduce neuropathic pain
DLK represents a compelling therapeutic target:
- Small molecule inhibitors: Several DLK inhibitors in development for ALS and peripheral neuropathy
- Gene therapy: Antisense oligonucleotides targeting DLK mRNA
- Combination therapy: DLK inhibition with other neuroprotective approaches
- DLK has both degenerative and regenerative roles — complete inhibition may impair nerve repair
- CNS delivery of inhibitors remains challenging
- Need to balance JNK pathway inhibition with normal cellular functions